Table 2. Disease characteristics at the time of oligoprogression.
| Variable | Values, n (%) |
|---|---|
| Type of immunotherapy (ICIs strategy) | |
| Monotherapy | 4 (26.7) |
| Combination | 7 (46.6) |
| None | 4 (26.7) |
| Lines of immunotherapy before oligoprogression | |
| First line | 8 (53.3) |
| Second line | 3 (26.7) |
| None | 4 (26.7) |
| Response to immunotherapy before oligoprogression | |
| CR | 0 |
| PR | 3 (20.0) |
| SD | 12 (80.0) |
| Number of oligoprogression | |
| One | 12 (80.0) |
| Two | 2 (13.3) |
| Three | 1 (6.7) |
| Organs of oligoprogression | |
| Lung | 17 (85.0) |
| Brain | 1 (5.0) |
| Lymph node | 1 (5.0) |
| Bone | 1 (5.0) |
| Pattern of oligoprogression | |
| New metastasis | 3 (20.0) |
| Existing metastasis | 12 (80.0) |
| Type of immunotherapy after oligoprogression | |
| Monotherapy | 15 (100.0) |
| Combination | 0 |
| Change of ICIs strategy | |
| Continue previous treatment or maintenance strategy | 6 (40.0) |
| Adjusted maintenance strategy | 9 (60.0) |
ICIs, immune checkpoint inhibitors; SD, stable disease; PR, partial response; CR, complete response.